Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
|
|
- Patrick Tyler
- 5 years ago
- Views:
Transcription
1 Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
2 I have no financial disclosures
3 Definition COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases. Global Initiative for Chronic Obstructive Lung Disease (GOLD),
4 Epidemiology of COPD 3 rd leading cause of death in US Oklahoma Prevalence is 8.2% COPD affects 24.1 million adults in US (12%) of adult population Patients > 65 years old COPD causes 20% of hospital admission ALA MMW 2013
5 Concept of Susceptible Smoker Smokers lose 60ml/year of lung function Non-smokers 30ml/year lung function COPD smokers lose > 60ml/year 15-20% of smokers develop COPD
6 Etiology Smoking + Pollutants Pathobiology Impaired Lung Growth Accelerated Decline Lung injury Lung & Systemic Inflammation Pathology Small airways disorders and abnormalities Emphysema Systemic Effects Airflow Limitation Clinical Manifestations
7 Screening for COPD No professional societies recommend screening for COPD in at risk patients currently Mainly secondary to cost associated with screening in aggregate No benefit to treatment of asymptomatic patients who have evidence of COPD on spirometry only Patients do need a good history to determine if they have symptoms Agency for Healthcare Quality Research 2005 Ann of Internal Medicine 2011;
8 Spirometry Does not measure response to treatment, better to follow symptoms No need for follow up spriometry once treatment initiated No evidence that spirometry results can be useful for patients who continue to use tobacco products Buffels Respir Med : Parkes BMJ 2008; 336: Stratelis Scan J Prim Health Care 2006; 24:133-9
9
10
11
12 Goals of Treatment Reduce long term lung function decline Prevent and treat COPD exacerbations Reduce hospitalizations Reduce mortality Relieve disabling dyspnea Improve exercise tolerance Improve quality of life ACP/ATS COPD Guidelines 2011
13 Tobacco Cessation #1
14 AECOPD Exacerbations are to COPD what myocardial infarctions are to coronary artery disease 8 billion per year in direct cost > 50 % of this is related to hospitalization for AECOPD 2/3 are associated with respiratory tract infection or air pollution 1/3 have no identifiable cause Reduce FEV 1 significantly during exacerbation any may not fully recover Chest 2015; 147(4)
15 Importance of preventing AECOPD Study of 351 patients with one or more AECOPD Patients with longer symptom duration Shorter interval between recovery and next exacerbation (p = 0.013) Lack of recovery of peak expiratory flow within 99 days was associated with viral symptoms at time of exacerbation Increased decline in lung function 10.8mL/year (p<0.001) AJRCC 2015 vol 192 (8)
16
17 Who is at risk? Patients with previous AECOPD Parameter HR HR (95% CI) P value Hosp. for COPD in past 12 months 2.71 ( ) <0.001 SGRQ increase 1.08 ( ) <0.001 FEV 1 drop by 5% 1.12 ( ) <0.001 Age (10y) 1.29 ( ) <0.001 Emphysema >5% CT WBC 1 X 10 9 /L 1.56 ( ) < ( ) <0.001 ECLIPSE Cohort Data Chest 2015; 147(4)
18 Who is at risk? Patients w/o previous AECOPD Parameter HR HR (95% CI) P value SGRQ increase FEV 1 drop >5% Emphysema >5% on CT 1.08 ( ) < (1.07-1,15) < ( ) <0.001 O2 use 1.75 ( ) <0.001 Age 10 y 1.24 ( ) <0.001 Asthma 1.45 ( ) <0.001
19 AECOPD Antibiotics + Steroids Steroids > 5 days showed no overall benefit no benefit to a long taper Oral steroids are equal to IV administration BIPAP for respiratory failure Chest (6) JAMA (22)
20 Management after Acute Exacerbation Mod. Severe COPD Very Severe COPD Long acting muscarinic antagonist inhaler Long acting beta agonist inhaler Placebo Long acting beta agonist and inhaled corticosteroid combination inhaler NOT ICS alone ACCP guidelines 2015
21 Management of Stable COPD Moderate /Severe Combination of long acting anticholinergic and long acting beta agonist OR Long acting anticholinergic monotherapy OR Long acting corticosteroid + beta agonist combo with long acting anticholinergic
22 GOLD guidelines for COPD Initially developed in 1997 Join effort of the National Heart, Lung, and Blood Institute and the World Health Organization Increase awareness of COPD
23
24 COPD Therapy - Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage of Disease Mild FEV 1 > 80% Moderate 50% < FEV 1 < 80% Severe 30% < FEV 1 < 50% Very Severe FEV 1 < 30% Risk factor reduction; immunizations; short-acting bronchodilator as needed One or more long-acting, scheduled bronchodilators; rehabilitation Inhaled steroid for frequent exacerbations Long-term O 2 ; surgical options
25
26
27 TORCH Trial 2007 Compared salmeterol + fluticasone (50/500) together and separate to placebo No difference in mortality compared to placebo Combination compared to placebo did have a reduced exacerbation rate, 1.13 vs 0.85 annual exacerbation rate (p < 0.001) Number needed to treat of 4 to prevent one exacerbation/year NEJM (8)
28 TORCH Salmeterol and fluticasone both also decreased exacerbations compared to placebo Fluticasone was associated with a higher risk of pneumonia 19.6% in combination therapy vs 12.3% in placebo ( p< 0.001) Hospitalization rates were 26% overall with a decrease of 17 % in salmeterol and combination group Number needed to treat of 32 to prevent one hospitalization per year NEJM (8)
29 UPLIFT Trial 2008 Compared tiotropium with placebo (patients were allowed to use other medications) No significant difference in FEV 1 or FVC between groups Decrease in time to exacerbation and total COPD exacerbations by 14% (p < 0.001) Decrease in respiratory failure RR 0.67 There was a decrease in mortality HR 0.87 (CI ) NEJM 2008; 359(15):
30 POET-COPD Trial 2011 Compared salmeterol vs tiotropium Tiotropium reduced the time to exacerbation compared to salmeterol 187 vs. 145 days (HR 0.83, CI ) Annual rate of mild exacerbation 0.64 vs 0.72 (p = 0.002) Annual rate of severe exacerbation 0.09 vs 0.13 (p < 0.001) NEJM 2011; 364 (12):
31 Reducing Lung Function Decline Nine trials show overall the inhaled therapies do reduce lung function decline Tiotropium (-2mL/year) compared to placebo Long acting corticosteroid (-8mL/year) Long acting beta agonist (-13mL/year) Inadequate evidence to predict which patients may have decreased lung function decline with inhalers. NEJM 2008; 359: BMJ 2000; 320: NEJM 2000; 343:
32 The oldie but goodies Tiotropium Aclidinium Ipratropium Salmeterol/fluticasone Formoterol/mometasone Formoterol/budesonide Albuterol
33 New Inhaler Combinations umeclidinium/vilanterol Compared to individual components alone Combo compared to UMEC showed improved FEV1 (p<0.001) Average was 60mL difference Improved SGRQ scores by 4 or more (49.3% vs 42%) Decreased COPD exacerbation (6.4% vs 8.6%) No difference in death rates Chest 2014; 145 (5) Lancet Resp Med 2014;2(6): Respir Med 2013;107(10)
34 New Inhaler Combinations umeclidinium/vilanterol Compare Combo to vilanterol alone Combo compared to VIL showed improved FEV1 (p < 0.001) Average was 110mL difference No significant difference in SGRQ (p=0.22) Reduced COPD exacerbations (6.1% vs 8.5%) There was a significant difference in the serious adverse events ( 3.8% vs 6.2%) Chest (2)
35 UMEC/VIL vs Tiotropium There was an improvement in FEV1 in UMEC/VIL of 90mL (p< 0.001) No difference in rates of serious adverse events (4.9% vs 4.7%) No difference in SGRQ score (p=0.56) No difference in COPD exacerbations (p = 0.80) No difference in death rates (p=0.21) Chest (2)
36 UMEC/VIL vs Salmeterol and fluticasone There was an improvement in FEV1 in the UMEC/VIL group (p <0.001) Average 90mL difference No difference in adverse events No difference in other study outcomes Chest (2)
37 New Combo Inhaler fluticasone/vilanterol Increase in pneumonia in patients treated with combination therapy Total 8 deaths Fewer exacerbations in the combo compared to vilanterol alone (p < ) No difference in FEV 1 between groups The Lancet Resp Med 2013 vol 1 (3)
38 Respimat Inhaler Device New device that uses a multi-dose propellant free system Liquid inhaler with aerosol generation that creates a mist Initial use started in 2004 Int J Chron Obstruct Disease V 1 (3)
39 Respimat
40 Respimat vs Other Devices One study in NEJM showed no different in inhaler devices with tiotropium 17,000 patients No difference in death No difference in COPD exacerbation No difference in FEV 1 NEJM (16)
41 New beta agonist olodaterol Approved for use by the FDA in 2014 Similar profile as other medications No serious adverse side effects compared to placebo
42 New Inhaler Combinations olodaterol/tiotropium Two studies with total of 5162 patients compare combined with individual components FEV1 improved in combo groups compared to tiotropium alone (p < 0.001) Approx- 117 ml SGRQ was improved (p < 0.05), questionable clinical significance only seen in higher dose Trend in improvement in exacerbation rate No difference in adverse events ERJ 2014
43 New Inhaler Combinations olodaterol/tiotropium Compared combo to olodaterol alone FEV1 was better in combo inhaler group (p < 0.001) approx. 108 ml SGRQ improved in combo group vs. olodaterol (p < 0.01), again may not be clinically sig. amt. Only showed trend in improvement in exacerbation rate No significant difference in adverse events ERJ 2014
44 and now, TRIPLE THERAPY Fluticasone, umeclidinum, and vilanterol together compared to other combinations FEV1 mean SGRQ score (lower is better) wk (ml) Change from baseline SGRQ 52 week Change from baseline Triple Fluticasone + Vilanterol Umeclidinim + Vilanterol NEJM 2018 vol 378 (18)
45 IMPACT Trial
46
47 but, can this be done in combo? Previous trial in American Journal of Respiratory and Critical Care published in 2009 compared tiotropium alone to budesonide/formoterol Patients with FEV1 < 50% and h/o exacerbation Improved FEV1 from baseline Improved SQRG Decreased exacerbations AJRCC 2009 vol. 180 pp
48
49 Other therapies Azithromycin for frequent exacerbation 1500 patients radomized to 250 mg azithromycin vs placebo Decreased time to exacerbation 266 days vs 174 (p<0.001) Decreased exacerbation rate 1.83 vs 1.43 (p=0.01) Hearing decrements higher in azithromycin group 25% vs 20% (p= 0.04) NEJM 2011 vol. 365(8)
50 Other therapies Roflumilast reduces COPD exacerbation Phosphodiesterase 4 inhibitor Specific patient patients with chronic bronchitis and airflow limitation and cough/sputum Decreased exacerbations both inpatient (p= 0.009) and outpatient settings (p= ) Another study showed decreased exacerbation by 14% (p 0.026) Int J Chron Obstruct Pulm Disease Resp Research :18 doi /
51 Other therapies Theophylline Narrow therapeutic window prevents significant use typically May reduce the number of exacerbations CHEST (4) N-acetylcysteine Recommended for patients with thick sputum as it reduces viscosity Exacerbation rate in one study was 1.16 compared to 1.49 in the placebo group More effective in GOLD II compared to III patients PANTHEON Lancet Resp Med (3)
52 Outpatient Oxygen in COPD Improves survival in patients with severe resting hypoxemia Arterial PO2 (PaO2) < 55 mmhg or arterial oxygen saturation (SaO2) < 88%. PaO mmhg or SaO2 = 89% if there is evidence of end-organ damage. Often prescribed for patients with nocturnal or exercise-induced hypoxemia but benefits less clear
53 PULM REHAB Endurance / Internal Training Condition the muscles of ambulation Improve cardio-respiratory fitness Reduce breathlessness & fatigue Resistance Training Unclear optimal amount Improves muscle mass ATS Advances in Palm Rehab 2013
54 PULM REHAB Inspiratory Muscle Training Decreases dyspnea Improves muscle endurance Flexibility No evidence of improvement Low testosterone Replacement improves muscle mass No evidence of improved strength
55 Surgical Options Lung Volume Reduction Surgery (NETT TRIAL ) Patients with apical emphysema + low exercise tolerance - better survival and functional status Apical emphysema + high exercise tolerance no change in survival, better functional status Non- apical emphysema no change in survival Not ideal for homogenous emphysema NEJM (21)
56 Best Practices Screen for Obstructive Sleep Apnea Patients will need an in lab study Monitor weight closely Vaccination (flu and pneumonia) Consider Pulm HTN if symptoms out of proportion to PFT Consider transplant in appropriate patient
57 Symptom Evaluation
58
59
60
61
62
63
64 Remember Alpha one Genetic cause of COPD ACCP guidelines recommend screening for all new diagnosis of COPD Gene allele testing or serum levels of alpha one anti-trypsin can be done Augmentation therapy may be of some benefit Genetic counseling is important AJRCC 1999 vol. 160 (5)
65 Minimal EvidenceTherapies High flow oxygen Home vent (noninvasive) for chronic respiratory failure
66 Thank you Any Questions?
COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationManagement of Acute Exacerbations of COPD
MiCMRC Educational Webinar Management of Acute Exacerbations of COPD August 22, 2018 MiCMRC Educational Webinar Management of Acute Exacerbations of COPD Expert Presenter: Catherine A. Meldrum PhD RN MS
More informationCOPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic
COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic Learning Objectives Know the adverse effects of COPD exacerbations Know mainstays
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationCOPD Update. Muhammad Talha Khan MD. COPD Exacerbations. COPD Clinical Importance. COPD Pathophysiology. Overview/Objectives
Overview/Objectives COPD Update Muhammad Talha Khan MD Pulmonologist St Croix Regional Medical Center, St Croix Falls, WI. Overview of COPD and disease impact Classification of COPD Severity Treatment
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationAt-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)
At-A-Glance Outpatient Management Reference f Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease Abstract Whittaker C, BPharm, MRPharmS Amayeza Info Centre Chronic obstructive pulmonary disease affects millions of people, has a major impact on quality of life
More informationCOPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center
COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Catherine Whittaker (BPharm, MRPharmS) Abstract Chronic Obstructive Pulmonary Disease affects millions of people, has a major impact on quality of life and has become
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationYou ve come a long way, baby.
COPD Dr Badri Paudel Dept of Medicine GMC/CHRC 4/22/12 badri@gmc 2 You ve come a long way, baby. Wayne McLaren Former Marlboro Man 4/22/12 badri@gmc 3 Age 30 a robust young man Age 51 riding into the sunset
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationCourse Handouts & Disclosure
COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationPulmonary and Critical Care Year in Review
Pulmonary and Critical Care Year in Review Heath E Latham, MD Assistant Professor University of Kansas Dept of Internal Medicine Division of Pulmonary and Critical Care None Disclosure Lung Cancer Screening
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MOUSTAPHA ABIDALI, DO CRITICAL CARE FELLOW UNIVERSITY OF ARIZONA- PHOENIX COPD OUTLINE Definition and Overview Pathophysiology Diagnosis and Assessment Therapeutic
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationOptimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center
Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationChanging Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH
More informationCOPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHQO s Episode of Care for Chronic Obstructive Pulmonary Disease
HQO s Episode of Care for Chronic Obstructive Pulmonary Disease Dr. Chaim Bell, MD PhD FRCPC Ontario Hospital Association Webcast October 23, 2013 Objectives 1. Describe the rationale and methodology for
More informationUpdate in Pulmonology Update in Medicine and Primary Care November 11, 2017
Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program
More informationPresenter Disclosure Information
12:45 1:3 pm Improving Outcomes in COPD SPEAKER Michael Campos, MD Presenter Disclosure Information The following relationships exist related to this presentation: Michael Campos, MD: No financial relationships
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationTake My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care
Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe
More informationObjectives. Advances in Managing COPD Patients
4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationAdvances in Chronic Obstructive Pulmonary Disease
Advances in Chronic Obstructive Pulmonary Disease By Dave C. Todd, MD; and Darcy D. Marciniuk, MD, FRCPC The case of Nina Nina, 64, presents to the clinic with a three- to fouryear history of progressive,
More informationMichelle Zeidler, MD, MS
7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationCOPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 9 PURPOSE To assure that DOP inmates with Pulmonary Diseases are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers and Chronic Disease Nurses are
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationEpidemiology of COPD Prof. David M. Mannino, M.D.
Epidemiology of COPD David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health College of Public Health University of Kentucky 1 Outline Definitions Severity Progression
More informationClass Update: Asthma / COPD Medications
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More information